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Purpose: Pathogenic variants in ARID1B are one of the most
frequent causes of intellectual disability (ID) as determined by
large-scale exome sequencing studies. Most studies published thus
far describe clinically diagnosed Coffin–Siris patients (ARID1B-
CSS) and it is unclear whether these data are representative for
patients identified through sequencing of unbiased ID cohorts
(ARID1B-ID). We therefore sought to determine genotypic and
phenotypic differences between ARID1B-ID and ARID1B-CSS. In
parallel, we investigated the effect of different methods of
phenotype reporting.
Methods: Clinicians entered clinical data in an extensive web-
based survey.
Results: 79 ARID1B-CSS and 64 ARID1B-ID patients were
included. CSS-associated dysmorphic features, such as thick
eyebrows, long eyelashes, thick alae nasi, long and/or broad
philtrum, small nails and small or absent fifth distal phalanx and
hypertrichosis, were observed significantly more often (p < 0.001) in
ARID1B-CSS patients. No other significant differences were
identified.
Conclusion: There are only minor differences between ARID1B-
ID and ARID1B-CSS patients. ARID1B-related disorders seem to
consist of a spectrum, and patients should be managed similarly.
We demonstrated that data collection methods without an explicit
option to report the absence of a feature (such as most Human
Phenotype Ontology-based methods) tended to underestimate
gene-related features.
Genetics in Medicine (2019) 21:1295–1307; https://doi.org/10.1038/s41436-
018-0330-z
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INTRODUCTION
The overall prevalence of intellectual disability (ID) has been
estimated at around 1%. Given the increasing number of
genes involved in ID, exome sequencing is becoming the first
method of choice to identify the underlying genetic cause in
patients with ID.1 This unbiased approach detects clearly
pathogenic variants in patients without the typically asso-
ciated phenotype, indicating that variability in expression is
higher than previously thought, confirming the existence of
ascertainment bias. This bias may be mitigated by establishing
the frequency of cardinal features in patients diagnosed
through sequencing of unselected populations, although
selection criteria for patients who undergo sequencing still
cause a degree of bias. However, studies in unbiased
populations suffer from another, less appreciated bias: they
may underestimate the frequency of cardinal features because
of the way that data are collected in large research studies. We
would like to coin this phenomenon “phenotype under-
reporting bias”: typically, a busy clinician is requested to
supply several Human Phenotype Ontology (HPO) terms,
and there is no guarantee that all features have been assessed
or that all the clinical information is reported by the clinician.
Consequently, it is not possible to make a distinction between
the absence of a feature and unknown status, especially when
specific diagnostic procedures are required to assess a feature
(e.g., a magnetic resonance image [MRI] scan for agenesis of
the corpus callosum [ACC]).
The ARID1B phenotype represents a good case study to
investigate these biases, because the associated phenotypes range
from clearly recognizable Coffin–Siris syndrome (ARID1B-CSS)
to less specific ID2,3 (ARID1B-ID). ARID1B is by far the most
frequently mutated gene (51–75%) (refs. 4–6) in Coffin Siris
syndrome (CSS) (OMIM 135900) and large-scale exome
sequencing studies invariably find that pathogenic variants in
ARID1B are among the most frequently identified causes in
unspecified ID cohorts (usually around 1%) (refs. 1,2).
CSS is characterized by “developmental or cognitive delay,
hypotonia, sparse scalp hair, distinctive facial features, aplasia
or hypoplasia of the distal phalanx or nail of the fifth and
additional digits, and hypertrichosis.”7 Approximately 70
ARID1B-CSS patients4–6,8–12 have been described. Roughly 30
ARID1B-ID patients have been described in some detail2,13–24
and an additional 23 patients with pathogenic variants in
ARID1B were identified in genome-wide research studies1,24
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where detailed clinical information is generally unavailable.
Data on the frequency of typical CSS features in the ARID1B-
ID population are lacking because a substantial number of
these patients were published before the link between
ARID1B and CSS was known. For example, in Hoyer et al.2
ACC was not specifically reported, although this is now
known as a frequent feature in ARID1B-CSS.11 Therefore, the
precise prevalence of these features cannot be estimated. The
availability of unbiased information is crucial now that exome
sequencing is being performed increasingly in neonatal and
prenatal settings, and a reliable prognosis can only be given
based on unbiased data.
The first aim of this study was therefore to overcome
ascertainment and phenotype underreporting biases, by
acquiring detailed clinical data of a large cohort of
ARID1B-ID patients. The second aim was to determine
whether the frequencies of features differ between ARID1B-
CSS and ARID1B-ID patients, as would be expected at least
for typical CSS features.
MATERIALS AND METHODS
Patient ascertainment
We developed a web-based survey (www.arid1bgene.com) based
on previously reported features of ARID1B patients. This website
is part of the Human Disease Genes website series (HDG), a
collection of websites aimed at informing professionals about
genes and copy-number variations and their clinical conse-
quences (http://humandiseasegenes.com/). The survey was open
to all clinicians of patients with pathogenic variants in ARID1B.
Data were contributed by pediatric neurologists, pediatricians,
and in most instances by clinical geneticists. Some clinicians
contacted us, others were approached based on publications,
conference presentations, submissions to databases like DECI-
PHER, or through large laboratories. We also included patients
from our previous studies4–6,9,11 and those referred to our
national CSS expertise center in Leiden, The Netherlands.
The institutional review board of the Leiden University
Medical Center, Leiden, The Netherlands provided an
approval waiver for this study.
Data assessment
When only partial variant data was given, the remaining
information was recovered using Alamut version 2.6.0. When
the standard deviation score (SDS) was not reported, but raw
data on weight, height, or occipital–frontal circumference
(OFC) was available, the SDS was determined using published
growth charts.25
After initial analyses we recontacted contributing clinicians
by email to inquire about features frequently reported in
open-ended questions.
We used a nominal p value of 0.05 as a cut-off for
significance. However, given that we assessed 90 features,
multiplicity correction by Bonferroni suggests that p values
above 0.0006 (0.05/90) should be treated with care. All analyses
were executed using SPSS version 23. R version 3.4.1 was used
to create graphs, including the survival package (version 2.41-3).
RESULTS
Data from 143 individuals with pathogenic variants in
ARID1B were included in the database. We received
additional data regarding features recurrently indicated in
our open-ended questions (Table 1 features marked with “+
+”, Supplementary Table S4) of 95 patients. Supplementary
Figure S1 displays facial photographs and hands or feet from
two ARID1B-ID and two ARID1B-CSS patients. Parents
provided consent for publication of these pictures.
Genotype
Figure 1 and Supplementary Table S1 provide an overview of
the submitted pathogenic variants. Sixty-two patients were
previously reported in literature.4–6,9,19,26 Pathogenic variants
were apparently de novo in all cases where parents could be
tested (107/107). In two sisters the same pathogenic variant
was found, while paternal DNA could not be obtained. Most
pathogenic variants were frameshift or nonsense (n= 118), 18
were deletions involving multiple or all exons, and 7 involved
canonical splice sites. One patient with a missense variant was
initially submitted but later retracted when the variant turned
out to be inherited from the unaffected father.
Phenotype
Patients’ characteristics are summarized in Table 1 and
Supplementary Table S2. Of the 143 individuals, 69 (48.3%)
were female and the age at follow-up varied between 0 and 51
years with a median of 10 years. ARID1B-ID patients were
less likely to be female than ARID1B-CSS patients (38 vs.
57%, p= 0.028). Two individuals have died, one of brain
swelling potentially due to low-grade brain stem encephalitis
that led to cardiorespiratory arrest at the age of 9 years, and
one suddenly after the age of 24 years of unknown cause.
Diagnosis before genetic testing
Seventy-nine ARID1B-CSS patients were included. Most
(91.5%) of the 64 ARID1B-ID patients were retrospectively
classified to fit the CSS spectrum by the referring clinician. An
overview of the clinical diagnoses prior to identification of the
pathogenic variant can be found in Supplementary Table S3.
No statistically significant differences in phenotypic features
were found between patients who were retrospectively
classified to fit the CSS spectrum by their referring clinicians
(n= 54) and those who were not (n= 5).
Comparison of the ARID1B-ID and ARID1B-CSS groups
As expected, ARID1B-CSS patients more frequently displayed
features associated with CSS than ARID1B-ID patients,
including thick eyebrows, long eyelashes, thick alae nasi,
long and/or broad philtrum, small nails and small or absent
fifth distal phalanx, and hypertrichosis (p < 0.0001–0.001,
Table 1).
ARID1B-ID patients appeared to have a higher prevalence of
myopia (p= 0.020), cryptorchidism (p= 0.023), constipation
(p= 0.002), sleep apnea (p= 0.026), hyperactivity (p= 0.026),
and high pain threshold (p= 0.044), although these differences
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Table 1 Clinical characteristics of ARID1B patients
Total ARID1B-CSS ARID1B-ID
Clinical featuresd n= 143 % n =79 % n =64 % p value Test
Sex (female) 143 48.3 79 57.0 64 37.5 0.028 a
Growth parameters & development
Gestational age, weeks (mean; SD) 133 39.0; 2.1 75 39.1; 2.0 58 38.9; 2.4 0.879 b
Birthweight (<–2 SDS) 129 5.4 74 6.8 55 3.6 0.506 c
Height at birth (<–2 SDS) 43 9.3 27 11.1 16 6.3 0.660 c
OFC at birth (<–2 SDS) 51 3.9 35 2.9 16 6.3 0.232 c
Age last measurements, years (median; min–max) 143 10; 0–51 79 10; 0–36 64 9; 0.5–51 0.682 b
Weight (<–2 SDS) 92 6.5 46 8.7 46 4.3 0.571 c
Height (<–2 SDS) 122 30.3 70 37.1 52 21.2 0.177 c
OFC (<–2 SDS) 105 2.9 63 3.2 42 2.4 0.670 c
Motor skills gross, delayed 103 99.0 46 97.8 57 100.0 0.447 c
Motor skills fine, delayed 100 95.0 44 97.7 56 92.9 0.381 c
Speech, delayed 131 65.6 75 68.0 56 62.5 0.106 c
Obstructive sleep apneae 71 8.5 34 0.0 37 16.2 0.026 c
Laryngomalaciae 90 19.8 47 17.0 44 22.7 0.466 a
Feeding difficulties 121 69.4 62 62.9 59 76.3 0.111 a
Start of feeding difficulties 71 34 37 0.345 c
Birth 76.1 76.5 75.7
Before 6 months 16.9 20.6 13.5
After 6 months 7.0 2.9 10.8
Duration of feeding problems 58 23 35 0.639 c
Brief 46.6 39.1 51.4
Several years 6.9 8.7 5.7
Ongoing 46.6 52.2 42.9
Tube feeding 65 16.9 22 13.6 43 18.6 0.409 c
0–6 months 10.8 4.5 14.0
6–12 months 3.1 4.5 2.3
1–3 years 1.5 0.0 2.3
Recurrent infections 75 57.3 30 63.3 45 53.3 0.391 a
Upper airway tract 17.3 10.0 22.2
Lower airway tract 2.7 0.0 4.4
ENT infections 12.0 10.0 13.3
Otitis media 14.7 13.3 15.6
Urinary tract 2.7 3.3 2.2
Neurological features
Intellectual disability 127 99.2 70 98.6 57 100.0 0.015 c
Normal–mild 3.1 1.4 5.3
Mild 28.3 38.6 15.8
Mild–moderate 15.7 8.6 24.6
Moderate 22.0 22.9 21.1
Moderate–severe 16.5 17.1 15.8
Severe 13.4 10.0 17.5
Hypotonia 116 81.0 71 80.3 45 82.2 0.795 a
Seizures 142 27.5 78 28.2 64 26.6 0.880 c
No seizures, but abnormal EEG 5.6 6.4 4.7
Seizure frequency 18 9 9 0.671 c
Once 27.8 11.1 44.4
Less than once a year 11.1 22.2 0.0
Once a year 33.3 44.4 22.2
Once a month 11.1 11.1 11.1
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Table 1 continued
Total ARID1B-CSS ARID1B-ID
Clinical featuresd n= 143 % n =79 % n =64 % p value Test
1/2 a month 5.6 0.0 11.1
≥2 per month 5.6 0.0 11.1
Agenesis of the corpus callosum 101 28.7 62 29.0 39 28.2 0.344 c
Partial/hypoplasia 13.9 17.7 7.7
Neuroradiology 47 87.2 17 94.1 30 83.3 0.305 a
Delayed myelination 17.0 11.8 20.0
Mega cisterna magna 14.9 23.5 10.0
Colpocephaly 10.6 11.8 10.0
Hypoplasia 4.3 0.0 6.7
Enlarged Virchow–Robin spaces 4.3 5.9 3.3
Vision and hearing impairments
Vision impaired 109 48.6 62 45.2 47 53.2 0.406 a
Vision problems 68 70.6 33 78.8 35 62.9 0.320 c
Astigmatism 16.2 24.2 8.6
Strabismus 30.9 36.4 25.7
Optic nerve hypoplasia 2.9 6.1 0.0
Nystagmus 8.8 6.1 11.4
Refraction error 10.3 9.1 11.4
Myopia 102 27.5 59 18.6 43 39.5 0.020 a
Hypermetropia 50 18.0 21 28.6 29 10.3 0.140 c
Abnormal eye exam 40 17.5 15 6.7 25 24.0 0.224 c
Hearing loss 122 22.1 71 18.3 51 27.5 0.157 a
Hearing loss, conductive 6.6 1.4 13.7
Hearing loss, bilateral 11.5 8.5 15.7
Hearing loss, unilateral 4.9 5.6 3.9
Eartubes 4.9 4.2 5.9
Start hearing problems, congenital 11 63.6 3 66.7 8 62.5 0.109 c
Hearing aid 5 80.0 2 100.0 3 66.7 0.665 c
Dysmorphic features
Coarse face 121 81.8 62 90.3 59 72.9 0.013 a
Hairline (low anterior and/or posterior) 91 69.2 45 75.6 46 63.0 0.196 a
Scalp hair, abnormal 129 79.1 78 83.3 51 72.5 0.141 a
Sparse 58.1 62.8 51.0
Forehead (broad or narrow) 95 42.1 49 28.6 46 56.5 0.000 c
Broad 22.1 6.1 39.1
Narrow 20.0 22.4 17.4
Eyelashes, long 131 63.4 79 75.9 52 44.2 0.000 a
Eyebrows, thick 134 81.3 78 91.0 56 67.9 0.001 a
Ptosis 133 20.3 77 20.8 56 19.6 0.872 a
Tear duct nonfunctioning or absent 93 15.1 54 16.7 39 12.8 0.609 a
Nasal bridge, abnormal 100 61.0 59 62.7 41 58.5 0.050 a
Wide 34.0 40.7 24.4
Flat 21.0 20.3 22.0
Broad 12.0 5.1 22.0
Nasal tip, abnormal 129 76 53 0.002 a
Broad 58.1 61.8 52.8
Upturned (anteverted nares) 29.5 39.5 15.1
Nose, abnormal 83 47.0 43 53.5 40 40.0 0.022 a
Short 26.5 39.5 12.5
Long 20.5 14.0 27.5
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Table 1 continued
Total ARID1B-CSS ARID1B-ID
Clinical featuresd n= 143 % n =79 % n =64 % p value Test
Alae nasi, thick 107 55.1 69 66.7 38 34.2 0.001 a
Nasal base, broad 88 48.9 48 43.8 40 55.0 0.392 a
Philtrum, abnormal 109 78.9 72 86.1 37 64.9 0.001 a
Short 24.8 29.2 16.2
Long 44.0 48.6 35.1
Broad 34.9 44.4 16.2
Mouth, large 131 68.7 75 76.0 56 58.9 0.037 a
Upper vermillion, abnormal 127 56.7 75 60.0 52 51.9 0.366 a
Thin 35.4 45.3 21.2
Thick 21.3 14.7 30.8
Lower vermillion, thick 125 69.6 76 78.9 49 55.1 0.005 a
Lower lip, drooping 71 56.3 30 76.7 41 41.5 0.004 a
Cleft palate/submucous cleft 90 6.7 35 14.3 55 1.8 0.031 a
Cleft palate 2.2 5.7 0.0
Bifid uvula 2.2 5.7 0.0
Submucous cleft 3.3 5.7 1.8
High arched palate 85 16.5 31 22.6 54 13.0 0.250 a
Ears, abnormal 122 52.5 66 57.6 56 46.4 0.433 a
Low-set 9.8 13.6 5.4
Posterior rotated 7.4 9.1 5.4
Hypertrichosis 128 86.7 76 94.7 52 75.0 0.001 a
Musculoskeletal anomalies
Scoliosis 123 26.0 70 27.1 53 24.5 0.743 a
Pectus, excavatum 104 13.5 57 14.0 47 12.8 0.850 a
Primary dentition, delayed 65 44.6 40 50.0 25 36.0 0.313 a
Permanent dentition, delayed 33 48.5 18 33.3 15 66.7 0.056 a
Widely spaced teeth 72 41.7 40 40.0 32 43.8 0.748 a
Bone age, delayed 40 47.5 30 46.7 10 50.0 1.000 c
Joint laxity 88 60.2 52 61.5 36 58.3 0.763 a
Early arthritis 75 5.3 36 5.6 39 5.1 1.000 c
Clinodactyly 77 36.4 42 45.2 35 25.7 0.076 a
Short phalanges 49 34.7 34 41.2 15 20.0 0.151 a
Complete absent or small 5th distal phalanx 110 40.0 66 60.6 44 9.1 0.000 c
Prominent distal phalanges; 102 24.5 64 31.3 38 13.2 0.040 a
Prominent interphalangeal joints 103 21.4 64 28.1 39 10.3 0.032 a
Brachydactyly general 60 16.7 19 15.8 41 17.1 1.000 c
Brachydactyly fifth finger 68 30.9 22 50.0 46 21.7 0.018 a
Small nails 122 54.9 73 68.5 49 34.7 0.000 a
Which nails, 5th finger and/or toe 106 55.7 67 65.7 39 38.5 0.007 a
Which nails, all 53 11.3 29 20.7 24 0.0 0.027 c
Fetal finger pads 100 29.0 50 26.0 50 32.0 0.509 a
Intestinal
Inguinal hernia 90 7.8 46 2.2 44 13.6 0.056 c
Intestinal problems 105 48.6 60 36.7 45 64.4 0.000 a
Constipation 30.5 21.7 42.2
Gastroesophageal reflux 17.1 13.3 22.2
Diarrhea 4.8 3.3 6.7
Pyloric Stenosis 2.9 5.0 0.0
Umbilical hernia 4.8 1.7 8.9
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are not statistically significant under the Bonferroni adjusted
significance level.
Regarding all other features, no significant differences were
found between the ARID1B-CSS and ARID1B-ID groups
(Table 1). Therefore, in the remainder of this section no
distinction is made between both groups.
Overall phenotype
Growth and development
Histograms of the standard deviations of height, weight, and
OFC are shown in Fig. 2a–c. A height below –2 SDS was
observed in 30.3%. Confirming our previous data,11 the
head circumference is normally distributed around 0 SDS
and only 2.9% have an OFC below –2 SDS. Developmental
milestones are shown in Fig. 2d, e. Speech, and gross and
fine motor skills were delayed in almost all patients.
Figure 2e shows the Kaplan–Meier plot of the age at first
words, and this plot suggests that about 25% of patients do
not develop speech.
Feeding difficulties were frequent (69.4%) and led to tube
feeding in 16.9% of patients. Bone age was delayed in 47.5%
and scoliosis occurred in 26.0% of patients. Frequent
Table 1 continued
Total ARID1B-CSS ARID1B-ID
Clinical featuresd n= 143 % n =79 % n =64 % p value Test
Cardiac & genitourinary anomalies
Cardiac anomalies 113 19.5 69 21.7 44 15.9 0.492 a
ASD 10.6 13.0 6.8
VSD 5.3 5.8 4.5
Renal anomalies 95 12.6 53 11.3 42 14.3 0.666 c
Renal sonography, abnormal 43 25.6 19 21.1 24 29.2 0.105 c
Cryptorchidism 65 55.4 28 39.3 37 67.6 0.023 a
Endocrinological abnormalitiese
Diabetes mellitus 71 7.0 43 7.0 28 7.1 1.000 c
Type 2 diabetes mellitus 4 75.0 2 100.0 2 50.0 1.000 c
Age (years) diagnosis (min–max) 2 18–46 1 18.0 1 46.0 0.317 b
Hypothyroidism 63 19.0 38 15.8 25 24.0 0.417 a
Age (years) diagnosis (median; min–max) 10 8; 1–40 4 4; 1.3–36.0 6 6; 1.0–40.0 0.394 b
Growth hormone deficiency 51 13.7 33 18.2 18 5.6 0.398 c
Growth hormone supplementation 50 12.0 31 16.1 19 5.3 0.387 c
Behavioral characteristics
Behavioral abnormalities 71 83.1 28 85.7 43 81.4 0.945 a
Hyperkinetic 15.5 14.3 16.3
Short attention 25.4 25.0 25.6
Impulsiveness 14.1 14.3 14.0
Obsessive 15.5 14.3 16.3
Rigid 8.5 3.6 11.6
Anger outbursts 16.9 10.7 20.9
Aggressive 16.9 14.3 18.6
Anxious 23.9 17.9 27.9
Poor sociability 19.7 17.9 20.9
Hyperactivity 63 42.9 25 60.0 38 31.6 0.026 a
High pain thresholde 47 40.4 28 28.6 19 57.9 0.044 a
Psychiatric disorders
ADHD 48 33.3 16 50.0 32 25.0 0.083 a
Autistic traits 77 57.1 27 66.7 50 52.0 0.215 a
Malignancies 97 1.0 53 0.0 44 2.3 0.454 c
Only characteristics present in ≥5% of all patients or in either patient group, characteristics differing between groups, and distinctive features are shown.
ADHD attention deficit hyperactivity disorder, ARID1B-CSS patient group with a suspicion of Coffin–Siris syndrome before genetic testing, ARID1B-ID patient group
with no suspicion of Coffin–Siris syndrome before genetic testing, ASD atrial septal defect, CSS Coffin–Siris syndrome, EEG electroencephalography, ENT ear nose
throat, OFC occipitofrontal circumference, SDS standard deviation score, VSD ventricular septal defect.
aChi-square.
bMann–Whitney U.
cFisher’s.
dThe total number of a feature can differ from the sum of subcategories, because in some cases it was possible to answer with more than one option or to report the
existence of a feature without specifying.
eData regarding these features were collected through email after first analyses.
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infections (57.3%) and gastrointestinal problems (48.6%,
mostly constipation) were also reported.
Congenital anomalies
Cardiac anomalies (19.5%), cryptorchidism (55.4%), laryngo-
malacia (19.8%), and a nonfunctioning or absent tear duct
(15.1%) were frequently reported. The cardiac anomalies
consisted mostly of abnormalities/defects of the cardiac septa
(n= 19) and/or mitral or aortic valves (n= 6). Renal
anomalies were present in 12.6% of patients. The most
frequent renal anomalies were hydronephrotic kidney (n= 3)
and nephrolithiasis (n= 3).
Neurological features
Almost all patients exhibited a variable degree of ID.
Figure 3a, b show the distribution of reported ID severity
and IQ scores (n= 35). Remarkably, several patients did have
an IQ in the normal range.
Hypotonia occurred in 81.0% of patients and 27.5% suffered
from seizures, while an additional 5.6% had an abnormal
ARID
1 2 3 4 5 6 7 8 9 1011 12 13 14 15 1617 18 19 20
Fig. 1 Overview of the location of pathogenic variants in ARID1B. Numbers represent exon numbers and a graphical representation of in-frame and
out-frame exons. When an exon ends with a complete codon, a vertical line is displayed. If it has one additional base an arrow to the left is displayed, and
two additional bases are indicated by an arrow to the right. In-frame exons thus have the same boundary on both sides of the exon. Small variants (defined
as events ≤20 bases) are identified by the arrows above the exon structure; larger variants are shown as lines under the intron–exon structure. All large
events were deletions. Only unique variants are shown. Uninterrupted lines represent variants in ARID1B-CSS patients; interrupted lines represent variants in
ARID1B-ID patients.
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Fig. 2 Biometry and developmental milestones. Histograms of the standard deviation score (SDS) of (a) height, n= 122; (b) weight, n= 92; and
(c) occipitofrontal circumference (OFC), n= 105. (d) Cumulative distribution of the developmental milestones walking (n= 117) and sitting (n= 85) for
ARID1B-CSS and ARID1B-ID. (e) Kaplan–Meier plot for the whole cohort of the age at which patients spoke their first words (n= 126). Confidence intervals
of Kaplan–Meier plots are generated by R’s survfit function.
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electroencephalogram (EEG). The age of onset of the seizures
varied from 0 to 14 years, with a median of 4 years (Fig. 3c).
The Kaplan–Meier plot suggests that about 40% of patients
are expected to experience one or more epileptic seizure
during their life. All patients responded well to seizure
medication (n= 18), while 4 did not receive medication.
Complete or partial ACC (42.6%) and delayed myelination
(17.0%) were the most prevalent cerebral anomalies.
Visual and hearing impairment
Vision problems (48.6%) were twice as frequent as hearing
problems (22.1%). Myopia was the most reported vision
problem (27.5%); severity ranged from –24 to –1.0 (median
–6.35). Hearing loss was congenital in most patients (63.6%)
and when present usually bilateral (51.9%); four patients
needed hearing aids.
Endocrinological features
Hypothyroidism was documented in 19.0% and one patient
had hypothyroidism for 2 years, which spontaneously
resolved. The Kaplan–Meier plot of age at which hypothyr-
oidism developed (Fig. 3d) suggests that the prevalence may
be 25%, but because the numbers are small there is a large
confidence interval. Of 71 individuals, 5 (7.0%) were
diagnosed with diabetes, 1 with hyperinsulinism, and 7/51
(13.7%) had a growth hormone (GH) deficiency, of which 6
received GH supplementation. We had no information on
whether GH deficiency was partial or complete.
Effect of location of pathogenic variant
The location of the pathogenic variant did not appear to
correlate with the severity of the phenotype (Supplementary
Figure S2). Because it has been reported that patients with
pathogenic variants in in-frame exons sometimes have less
severe phenotypes because of naturally occurring exon
skipping,27 we compared the phenotypes of patients with
pathogenic variants in in-frame exons versus those with
pathogenic variants in out-frame exons. We classified patients
with pathogenic variants in the first and last exon and whole-
gene deletions as out-frame, because such pathogenic variants
cannot be rescued by exon skipping. Most pathogenic variants
were classified as out-frame (84.6%), which was expected
because 86.1% of the coding region consists of out-frame
exons. We did not find any differences in the phenotype
between these two groups.
DISCUSSION
Genotype
Information on 143 patients with pathogenic variants in
ARID1B was collected. In accordance with previous studies,
all pathogenic variants were truncating (nonsense, frameshift,
splice-site, and deletions of various numbers of exons
including whole-gene deletions). In addition, four transloca-
tions14,15,28,29 and three duplications2,16,21 affecting ARID1B
have been reported in literature. While previous reviews30,31
have suggested that a pathogenic missense variant was
reported in Tsurusaki et al.,9 it is worth noting that a
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nonsense variant in ARID1B was also found in the same
patient. Although parental DNA was not available for this
patient, it seems most likely that the missense variant was
harmless, while the nonsense variant was causal. Yu et al.16
described two pathogenic de novo missense variants in
patients with short stature, but without ID or speech delay.
Mignot et al.32 described a patient with mild ID and ACC who
inherited a pathogenic missense variant from a mildly affected
mother. Because the pathogenic variant (c.6092 T>C;
p.Ile2031Thr) arose de novo in the mother, it is highly likely
to be pathogenic. Thus, missense variants appear to be a much
less common cause of ID than truncating variants. Missense
variants identified in the absence of parental DNA should be
interpreted with caution and are much more likely to be
harmless. Care should also be taken with the interpretation of
de novo missense variants in patients with ID.
As suggested by Johnston et al.,33 it is important to take
note if pathogenic variants in the same exon have been
previously described when interpreting variants, because
some annotated exons might in fact not be relevant for
disease-associated transcripts. It is therefore noteworthy that
we have not identified any pathogenic variants that only affect
exon 3 (Fig. 1). Exon 3 is a small in-frame exon and we
previously indicated11 that truncating variants in this exon are
most likely benign. Indeed, Johnston et al.33 report an
inherited truncating variant in exon 3 in a patient without
an ARID1B-related phenotype. Taking all evidence together,
it is most likely that pathogenic variants in exon 3 are
nonpathogenic, and that transcript NM_017519.2, which
lacks exon 3 of NM_020732.3, is in fact the more relevant
transcript. Another remarkable aspect that is apparent
from Fig. 1 is that no pathogenic variants have been
reported in the first 849 bases of ARID1B. Although some
frameshift variants are reported in gnomAD, these are
dubious calls because the variants are in a low-complexity
region. The lack of pathogenic variants may be by chance
or due to sequencing difficulties in this GC-rich area, but
it is also possible that there is an alternative start site
that renders truncating variants in the first part of exon 1
neutral. Therefore, we advise caution when interpreting
such variants.
Although a previous analysis seemed to suggest that
pathogenic variants in the last exon might result in a more
severe phenotype,11 repeating this analysis with the current data
did not confirm this suspicion (Supplementary Figure S2).
Penetrance
Penetrance of rare variants cannot be directly estimated, but
the inheritance status and prevalence of apparently patho-
genic variants in population databases can be used as proxy.34
Pathogenic variants were de novo in all cases where
inheritance could be established (n= 107). We did observe
two sisters with the same pathogenic variant, and although
this could be due to paternal inheritance, the most likely
explanation is gonadal mosaicism, as previously described for
ARID1B.17
The gnomAD browser may be viewed as a large population
data set, consisting of exomes and genomes of unrelated,
unaffected individuals sequenced as part of disease-specific
and population genetic studies. In transcript NM_020732.2
(ENST00000346085), fewer missense variants in ARID1B are
reported than would be expected if these were to occur
randomly (ExAC accessed 10 April 2018; 744.4 expected, 555
observed, z-score of 3.39). Ten loss-of-function variants are
reported; half of these might not be pathogenic because they
are either in the start of exon 1, or in exon 3 (Supplementary
Table S5). The other five variants, three splice-site variants
and two frameshift variants, are potentially pathogenic. This
might suggest that the penetrance of pathogenic variants in
ARID1B is not complete, and that these individuals had an
average IQ as some of the individuals in our study. Therefore,
while the penetrance of pathogenic variants in ARID1B
appears to be very high, we still recommend parental testing,
especially when future pregnancies are considered.
Phenotype
The main differences between ARID1B-CSS and ARID1B-ID
seem to be related to dysmorphic features. Therefore, we
conclude from this data set that the ARID1B-related disorders
represent a spectrum. Not every feature is present in all patients,
and depending on the combination of features present, and the
experience of the clinician concerned, a patient might receive a
clinical diagnosis of CSS. Although the patients in our previous
ARID1B-CSS cohort11 had an equal sex ratio, our current cohort
finds significantly more females than males in the ARID1B-CSS
group compared with the ARID1B-ID group. This may be
because some features, most notably hypertrichosis, are easier to
recognize as abnormal in females than in males.
Endocrinological features
Hypothyroidism was reported in 12/63 patients, and most
were diagnosed before the age of 15 years (Fig. 3d). Diabetes
was diagnosed in 5/71 patients; 4 of these patients were
reported to have type 2 diabetes and had a relatively high
weight, while one was diagnosed with type 1 diabetes, and 1
patient was diagnosed with hyperinsulinism. This patient with
hyperinsulinism has been described previously,19 and one
additional patient has been reported to have hyperinsulin-
ism.10 Of our patients, 7/51 were diagnosed with GH
deficiency, and 6 of those received GH supplementation.
Likewise, several patients with a growth delay due to GH
deficiency were described16 and a similar phenomenon was
replicated in an Arid1b heterozygous mouse model.35
Considering 30% of patients had short stature (<–2 SDS),36
GH deficiency could be an underrecognized feature of
ARID1B patients.
Cancer
Somatic variants in ARID1B have been associated with several
types of cancer.37 However, only one case is known of a patient
with a pathogenic germline variant in ARID1B and (thyroid)
cancer.38 Similarly, in our cohort only one patient had
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malignancies. This boy had a Sertoli–Leydig cell tumor at the
age of 3 and a temporal glioneuronal tumor at 12 years of age.
No genetic testing was performed in this patient to detect the
presence of specific tumor syndromes. Based on our patient
cohort it seems unlikely that pathogenic germline variants in
ARID1B confer an increased cancer risk, but longer follow-up of
our patients is needed to make a definitive statement.
Phenotype delineation methods and biases
The increased awareness of ascertainment bias and the
increasing number of newly discovered disease genes have
resulted in new methods for data collection. Paper ques-
tionnaires and Excel spreadsheets are rapidly being replaced by
Internet forms and HPO-based methods along with more
formal registry software interfaces such as PhenoTips.39 For the
current study we have chosen to use an online questionnaire
based on our previous data, with mostly fixed answers. More
general genetic databases (such as DECIPHER40) accommodate
inclusion of phenotypic data by using HPO terms. Whereas
HPO-based methods allow for more straightforward identifica-
tion of new, unexpected findings, our approach with specific
questions allows calculation of true frequencies of features,
because we can discriminate between absence of a feature and
missing data. To investigate whether this influences results, we
compared our data regarding the phenotype of ARID1B
patients with the features reported for ARID1B patients in the
DECIPHER database. It should be noted that there are some
patients who are both in our cohort and the DECIPHER
database. On 2 October 2017 DECIPHER contained 54 open-
access ARID1B patients with 247 phenotypic features. Except
for laryngomalacia and excessive salivation and/or drooling, all
characteristics enriched in ARID1B patients in DECIPHER had
been included in our questionnaire. The DECIPHER frequency
of all reported features was lower than ours, a difference that
was statistically significant for most (Supplementary Table S6).
In addition to other phenotypic features, growth and
development are graphically represented on the DECIPHER
website. We replicated some of these graphs and found only
minor differences, which may be explained by the increased
volume of data available to us (Supplementary Table S7 and
Supplementary Figure S3).
Based on these results, we conclude that the DECIPHER
database is a valuable tool to assess the potential features that
ought to be included in gene-specific phenotype question-
naires, but the reported percentages are potential under-
estimations, likely due to phenotype underreporting bias
owing to their data collection method. This bias could be
mitigated by developing an adaptive questionnaire, so that
submitters are requested to include or actively exclude
features that have been mentioned several times in patients
with the same underlying genetic cause.
Another bias that is present in most cohorts is an age-
related bias. Most of our population is young, and this
precludes us from detecting features that typically present at
later age. This bias can partially be resolved by performing
survival analysis, as we have done for speech, seizures, and
hypothyroidism. In all cases there was a clear difference in our
global frequency estimate, and the estimate provided by the
Kaplan–Meier plot. We therefore recommend that authors of
clinical cohorts include the age of occurrence of age-
dependent features and perform survival analysis.
Study limitations
Our study has several limitations. Data entry was performed by
many different clinicians, which could have led to different
interpretation of subjective questions, such as whether the
patient fits the CSS spectrum. During this study, it became
evident from literature and the DECIPHER database that
previously unknown features, such as laryngomalacia, were part
of the ARID1B spectrum and should have been added to our
questionnaire. The effect of these incompletions was mitigated
in part by the presence of an open field and our request to the
contributing clinicians to send us an update on their patient’s
characteristics for frequently reported additional features.
Although we have attempted to account for different sources
of bias, we cannot exclude that we currently overestimate the
presence of some features, because our calculation is based on
those patients having the feature, divided by those who are
reported not to have the feature. It is possible that in some cases
the absence of a feature is not consciously recognized or
recorded in the clinical charts, which may result in scoring
“unknown” rather than “absent” for a given feature. This bias
can only be mitigated by thoroughly phenotyping every patient
by a limited number of physicians, and is something we are
planning to do with our national CSS cohort in the near future.
Conclusion
We conclude that the ARID1B-related disorders encompass a
spectrum of features. The typical ARID1B patient has ID,
feeding difficulties, laryngomalacia, speech delay, motor delay,
hypertrichosis, and cryptorchidism. Our data suggest that
endocrinological abnormalities, in particular hypothyroidism,
may also be part of the ARID1B spectrum, but further
research is needed to confirm this finding. There are few
differences between ARID1B-CSS and ARID1B-ID, and we
recommend that patients should be managed similarly. Based
on the clinical data presented here we update our previous
recommendations11 for the management of ARID1B patients:
At the time of diagnosis
– Rule out congenital anomalies by performing renal and
cardiac ultrasounds. Thoroughly check for cryptorchidism
and laryngomalacia as indicated.
– Refer to clinical geneticist for counseling.
At the time of diagnosis and at follow-up
– Evaluate growth; consider referral to endocrinologist
when significantly delayed.
– Evaluate hearing and vision regularly.
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– Consider an EEG if there is a suspicion of seizures.
– Evaluate feeding problems. Offer dietary advice and
feeding management. Consider evaluation by a gastro-
enterologist and/or a swallowing study.
– Treat constipation adequately.
– If indicated, early intervention using speech and/or
physical therapy.
– Yearly evaluation of development by a specialized
pediatrician and implementation of a specialized educa-
tion plan for school or daycare as indicated.
– Periodic evaluations for scoliosis.
– On indication, determine thyroid status and glucose
concentrations.
We also recommend periodic evaluation by a team of
professionals specializing in ARID1B-related disorders (e.g.,
pediatrician, pediatric physiatrist, physical therapist, speech
therapist, behavioral specialist, pediatric neurologist, clinical
geneticist), which may take place at a distance.
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